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Tweet: @ufdiabetes investigators demonstrate dysregulated expression of monogenic diabetes-
associated genes in human type 1 diabetes pancreas, highlighting an activated integrated stress 
response as a feature and perhaps driver of the disease.  
ABSTRACT 
Type 1 diabetes has a multifactorial autoimmune etiology, involving environmental prompts and 
polygenic predisposition. We hypothesized that pancreata from individuals with and at risk for 
type 1 diabetes would exhibit dysregulated expression of genes associated with monogenic forms 
of diabetes caused by non-redundant single-gene mutations. Employing a “monogenetic 
transcriptomic strategy,” we measured the expression of these genes in human type 1 diabetes, 
autoantibody positive (autoantibody+), and control pancreas tissues using RTqPCR in accordance 
with the Minimum Information for Publication of Quantitative Real-Time PCR Experiments 
(MIQE) guidelines. Gene and protein expression were visualized in situ using 
immunofluorescence, RNAScope, and confocal microscopy. Two-dozen monogenic diabetes 
genes showed altered expression in human pancreata f om individuals with type 1 diabetes versus 
unaffected controls. Six of these genes also saw dysregulation in pancreata from autoantibody+ 
persons at increased-risk for type 1 diabetes. As a subset of these genes are related to cellular stress 
responses, we measured integrated stress response (ISR) genes and identified 20 with altered 
expression in type 1 diabetes pancreata, including three of the four eIF2α-dependent kinases. 
Equally intriguing, we observed significant repression of the three arms of the ISR in 
autoantibody+ pancreata. Collectively, these efforts suggest monogenic diabetes and ISR genes 
are dysregulated early in the type 1 diabetes disease process and likely contribute to the disorder’s 
pathogenesis. 
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Type 1 diabetes is widely considered a multifactorial disorder, polygenic in etiology with 
environmental factors thought to contribute toward pathogenesis, resulting in autoimmune 
destruction of insulin producing pancreatic β-cells (1; 2). In contrast, monogenic diabetes 
comprises an expanding group of rare heterogeneous, single gene disorders with a collective 
prevalence of ~1-5% of all diabetes cases, depending on age of onset, geography and ethnicity (3-
6). Monogenic forms of diabetes distinguish critical proteins within human β-cell development 
and biology where no sufficient compensatory proteins or pathways exist in the presence of a 
sufficiently deleterious mutation, reflecting the criti al nature of the protein and a lack of 
“redundancy” at that point within the affected pathway. Most forms of monogenic diabetes result, 
through a variety of mechanisms, in a reduced ability to process or secrete insulin, with some 
variants associated with insulin resistance (7).  
We therefore studied genes associated with monogenic forms of diabetes with the rationale 
being a relevance to disease pathology. Traditionally, these non-redundant forms of diabetes have 
been classified based on age of onset: (Maturity Onset Diabetes of the Young (8-10) (MODY); 
neonatal diabetes mellitus (11; 12) (NDM) which includes transient (TNDM1 and TNDM2) and 
permanent NDM (PNDM) or as syndromic. However, to pr vide a physiological reference point, 
we have addressed the biological heterogeneity of monogenic diabetes genes, by separating our 
studied genes into four physiological groups: immune, β-cell function, β-cell development and 
endoplasmic reticulum (ER) function/stress. 
We therefore hypothesized that a phenotypic assessment of gene expression levels for the ever-
expanding cohort of genes linked to monogenic diabetes could be enlightening in our 
understanding of multifactorial/polygenic type 1 diabetes disease etiology and pathogenesis. In 
particular, we have sought to address the question of the importance of genes causative in 
monogenic diabetes using real time qPCR (RTqPCR), immunofluorescence (IF), and in situ 
hybridization (ISH) studies on human pancreatic tissues from unaffected control, type 1 diabetes, 
autoantibody positive (autoantibody+, high risk fortype 1 diabetes), and type 2 diabetes organ 
donors from the Network for Pancreatic Organ donors with Diabetes (nPOD) repository.  
 
Research Design and Methods 
Donors The JDRF nPOD program (www.jdrfnpod.com) recovers transplant-quality pancreata 
from organ donors as previously described (13). All procedures were approved by the University 
of Florida Institutional Review Board and the United Network for Organ Sharing (UNOS) 
according to federal guidelines, with informed consent obtained from each donor’s legal 
representative. For each donor, a medical chart review was performed in addition to assays for 
type 1 diabetes-associated autoantibodies and C-peptide (14), with type 1 diabetes diagnosed 
according to the guidelines established by the ADA (15). Patient #, autoantibody+ status, age, 
disease duration, gender, ethnicity, C-peptide, HbA1c, BMI, cause of death, and hiRES HLA were 
obtained from nPOD records (Table S1). Cause of death w s validated via an independent medical 
chart review by a medical expert. 
Sample processing and RNA extraction Pancreata were recovered, placed in transport media on 
ice, and shipped via organ courier to the University of Florida where tissues were processed by a 
licensed Pathology Assistant as previously described (13). Tissue from pancreas was preserved as 
flash frozen or in RNAlater (Qiagen, Valencia, CA) an average of 16h from cross clamp. Total 
RNA was isolated following homogenization in Qiagen RNeasy Plus Mini Kit isolation buffer as 
per the manufacturer’s instructions including treatment with DNase 1. RNA concentrations were 
determined using a Nanodrop 2000C (Thermo Scientific, Waltham, MA) and when necessary, 
integrity was verified by visualization of ribosomal RNA by gel electrophoresis and ethidium 
bromide staining. 
RTqPCR, gene stability ranking and qPCR minimum guidelines All samples were confirmed 
to be free of DNA contamination in controls with an intron/exon primer pair and without reverse 
transcriptase. cDNA was produced with SuperScript II (Invitrogen, Carlsbad, CA) using oligo dT 
priming and subsequently utilized for RTqPCR using Thermo Luminaris Color HiGreen 
Fluorescein qPCR Master Mix (Thermo Scientific). 0.5-1 µg of total RNA was used for each 20 µl 
cDNA reaction which was then diluted to 200 µl and 2 µl of diluted cDNA employed for each 
25 µl RT-qPCR reaction containing 600 nM of each prime  pair. Individual RT-qPCR reactions 
were carried out in duplicate in a Biorad MyiQ. All samples were standardized for experimental 
design, nucleic acid isolation, measurement of total RNA concentration, reverse transcription, 
primer design/target specificity (16) and all RTqPCR parameters (17) in accordance with the 
Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) 
guidelines. 
The MIQE guidelines (Table S2) were implemented to ensure the reliability/integrity of 
scientific data and to provide for experimental transparency/consistency amongst laboratories (17). 
Table S2 illustrates a checklist for MIQE guidelines, which were followed in this publication. A 
fundamental axiom of MIQE is normalization of RTqPCR data by utilizing multiple reference 
genes (RGs) to address intra- and inter-kinetic variations in qPCR studies (18; 19). The following 
genes were identified as potential RGs based on the lowest standard deviation (SD) and coefficient 
of variation (CoV) of un-normalized Cq values across all unaffected and type 1 diabetes pancreata: 
ASNS (asparagine synthetase), GLP1R (Glucagon-like peptide 1 receptor), MAFB (V-maf 
musculoaponeurotic fibrosarcoma oncogene homolog B), NKX6-1 (NK6 homeobox 1), NRP1 
(Neuropilin 1), PFKM (phosphofructokinase, muscle), PPIA (cyclophilin A), and GCG 
(glucagon). To compare and rank potential reference genes with the lowest variation and highest 
stability across the control and type 1 diabetes pancreata, four algorithms were evaluated 
simultaneously using the Web-based tool, RefFinder (20) (https://github.com/fulxie/RefFinder) 
which incorporates four well accepted algorithms: geNorm (21), Normfinder (22), BestKeeper 
(23), and the comparative delta-Ct method (24) as well as its own comprehensive assessment (20). 
RefFinder requires an equal number of data points for all genes evaluated, therefore, only 45 
donors were included in this analysis. RefFinder idntified three human pancreas specific reference 
genes (RGs) demonstrating the most stable expression in human pancreata, PPIA (SD=2.02; 
CoV=0.06), MAFB (SD=1.89; CoV=0.07) and ASNS (SD=2.15; CoV=0.07). We then utilized the 
geNorm algorithm (21) to generate separate normalization factors derived from the geometric 
mean of these RGs: PPIA, ASNS and MAFB for unaffected and the type 1 diabetes cohorts, 
respectively. The normalization factors were applied to the analysis of all monogenic diabetes and 
ISR genes to report quantitative changes in gene expression between unaffected and type 1 diabetes 
pancreata, with the fold difference (FD) reported as the ratio of the means (type 1 
diabetes/Unaffected). PPIA (cyclophilin A) also served as the inter-run calibrator. Using the 
interquartile range outlier test (25; 26), only extr me outliers defined as values below Q1-3(Q3-Q1) 
or above Q3+3(Q3-Q1) (where Q1 and Q3 are the first and third data quartile) were identified and 
excluded from statistical analyses 
(http://www.itl.nist.gov/div898/handbook/prc/section1/prc16.htm).  
Primer design The respective monogenic diabetes genes analyzed in this study were selected 
based on review of the National Center for Monogenic Diabetes at the University of Chicago, 
Kolver Diabetes Center (http://monogenicdiabetes.uchicago.edu), the Institute of Biomedical and 
Clinical Science, University of Exeter, Medical School 
(http://medicine.exeter.ac.uk/research/biomedicalclinical/moleculargenetics-monogenic/) and 
OMIM (https://www.omim.org). We would like to point out, however, that this may not be an all-
inclusive set of monogenic diabetes genes. Human gee symbols, based on HGNC 
(http://www.genenames.org) were used throughout this study with gene names, chromosomal 
location, NCBI accession numbers, common protein names, OMIM #, chromosomal location, 
genomic coordinates, MODY number, Neonatal Diabetes M llitus classification and appropriate 
references provided in Table S3. We utilized the public Primer-Blast software 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/ (16)) which incorporates the Primer3 program 
(27) for primer design, genome-wide BLAST analysis along with the Needleman-Wunsch global 
alignment algorithm (28) to identify internal homology between primers and any unwanted targets 
in the human genome. This satisfies the requirements for primer specificity compared to both the 
human transcriptome and genome.  Primers were designed, when possible, as exonic primers 
spanning an intron, with comparable GC content and an optimal Tm of 60 °C (Table S4). 
 
Immunofluorescence (IF) Immunofluorescence staining was completed using the PerkinElmer 
Opal 4-Color IHC Kit (Perkin-Elmer NEL810001KT, Waltham, MA) as per the manufacturer’s 
instructions. After deparaffinization and rehydration, all slides were subjected to a microwaved 
treated antigen retrieval step using kit’s appropriate AR buffer. Slides were then incubated in 
Antibody Diluent / blocking solution followed by incubation with primary antibody in Antibody 
Diluent / blocking solution. Slides were stained with the following antibodies: insulin (Dako, 
A0564, RRID:AB_10013624) ; somatostatin (Dako A0566, RRID:AB_2688022); glucagon 
(Abcam ab10988, RRID:AB_297642); STAT5 (LifeSpan BioSciences LS‑B5540, 
RRID:AB_10915294); GLIS3 (Sigma/Aldrich HPA056426, RRID:AB_2683128); GATA4  
(Santa Cruz sc-25310, RRID:AB_627667); WFS1 (LifeSpan BioSciences LS‑B14378); and 
EIF2AK3/PERK (Proteintech 24390-1-AP). For detection and visualization, slides were subjected 
to the Polymer HRP Ms + Rb and the TSA Plus Fluorescent system (Perkin-Elmer NEL703001KT, 
NEL741001KT, NEL744001KT, NEL745001KT Waltham, MA). Coumarin (Maxima Excitation 
402 nm; Emission 443 nm) was assigned to insulin; Fluorescein (Maxima Excitation 494 nm; 
Emission 517 nm) was assigned to somatostatin; gene of i terest (STAT5, WSF1, GATA4, GLIS3 
and EIF2K3) to CY3 (Maxima Excitation 550 nm; Emission 570 nm); and glucagon to CY5 
(Maxima Excitation 648 nm; Emission 667 nm). For each panel, negative and positive control 
slides were also stained to determine the exposure time and image processing necessary to provide 
optimal visualization of antibody signal. All images were captured and processed using an IX73 
Olympus florescence microscope using cellSense software.  
RNAscope coupled with immunofluorescence Fluorescent-labeled RNA probes (STAT5B, Cat. 
Nb. PN 501151; GLIS3, Cat. Nb. PN 525701-C3; GATA4, Cat. Nb. PN 579821; WFS1, Cat. Nb. 
PN 436081; EI2AK3, custom reagent (targeting 330-1487 of NM_001313915.1); PPP1R15A, Cat. 
Nb. PN 311141; PSEN1, Cat. Nb. PN 502001; COL6A2, Cat. Nb. PN 482611; ERN1/IRE1, Cat. 
Nb. PN 497331-C2; Hs-PPIB (positive control) Cat. Nb. 313901, DapB (negative control) Cat. 
Nb. 310043) were purchased from ACD (Advanced Cell Diagnostics, Inc.; Newark, CA). RNA 
staining was performed with an RNAscope® Multiplex Fluorescent Reagent Kit v2 (PN 323100) 
according to the manufacturer’s instructions: Slides w re dewaxed 2x 5min in Xylene and 2x 2min 
in 100% EtOH then air dried. Antigen retrieval was performed for 15min using RNAscope® 1X 
Target Retrieval Reagents heated up to 98°C. Slides were dipped in ddH2O then 100% EtOH for 
2min and air dried. RNAscope® Protease III was applied to the dry slides and incubated for 30min 
at 40°C in the oven then rinsed with RNAscope® 1X Wash Buffer. After incubation with RNA 
probes for 30min at 40°C, probes were amplified using RNAscope® Multiplex FL v2 AMP 1 for 
30min, then RNAscope® Multiplex FL v2 AMP 2 for 30min, RNAscope® Multiplex FL v2 AMP 
3 for 15min and RNAscope® Multiplex FL v2 HRP-C1 for 15min. All amplification steps were 
performed at 40°C and slides washed between steps in RNAscope® 1X Wash Buffer 2x 2min. 
Signal was developed using TSA® Plus Cyanine 3 (NEL744001KT) 1:1500 for 30min at 40°C 
and blocked with HRP Blocker for 15min at 40°C. Slides were washed in TBS and incubated 
overnight at 4°C with primary antibodies (mouse anti-CD99, Biolegend Cat. Nb. 318002, clone 
HCD99, RRID:AB_604112, 1:200 and rabbit anti-Cytokeratin 19, Cell Signaling Technologies 
Cat. Nb. 13092, clone D7F7W, 1:100). The next day, slides were washed in TBS and incubated 
for 2h at room temperature with secondary antibodies (goat anti-rabbit Alexa Fluor 488, Thermo 
Fisher Cat. Nb. A-11008, and goat anti-mouse Alexa Fluor 647, Thermo Fisher Cat. Nb. A-21235). 
Images were acquired on a Leica DMI 6000 widefield microscope. 
Confocal microscopy Samples were imaged on a Nikon A1plus confocal microscope using a 20X 
(NA0.75) air objective (Nikon Instruments, MellvilleNY). Excitation and emission for each target 
were as follows: insulin Ex441/Em450; somatostatin Ex488/Em525; WFS1/STAT5B 
Ex561/Em595; glucagon Ex647/Em700. 3D Z-stacks were constructed with a 2.5 µm step size 
and compressed to a 2D maximum intensity projection for display. All images for a given gene and 
condition (i.e. WFS1 healthy control) are displayed with identical lookup table values. Imaging 
parameters (laser power, pixel dwell, pinhole size, gain, offset) remained constant for all samples. 
All raw images of single islets were denoised in Nikon Elements (Nikon Instruments, Mellville, 
NY) for display. 
Statistical analysis For each patient population, a two-tailed Wilcoxon ra k-sum test comparing 
unaffected versus disease patients was performed for each gene. The Storey method was used to 
control the false discovery rate (FDR); the adjusted p-values (q-values) were estimated using 
the qvalue R package (http://github.com/jdstorey/qvalue) with lambda=0. Q-values < 0.024 were 
considered to be statistically significant. R (v3.6.1) was used for all calculations.  GraphPad Prism 
v8.0 (La Jolla, CA) was used for all graphical presentations. 
Results 
Of relevance to the quality of human donor pancreatic RNA for gene expression analysis 
(29-32), normalized expression levels for ASNS, GCG, GLP1R, NRP1, and PFKM were not 
significantly different across donors grouped when correlated with cause of death (head trauma, 
anoxia or cerebrovascular/stroke), ICU or organ trasport times. A summary of metadata appears 
in Table S1 where subsets of unaffected controls and T1D are analyzed in experiments reported 
below. 
 
Some Monogenic diabetes genes in type 1 diabetes, autoantibody positive and type 2 diabetes 
donor pancreata are differentially expressed. 
Overall 24 of the 45 monogenic diabetes genes showed an increased expression in T1D pancreas 
(Table 1). We then examined these 24 monogenic diabetes genes differentially expressed in the 
type 1 diabetes pancreas in organs from a population of autoantibody+ donors (n=20-24) 
considered at risk (33) for type 1 diabetes, as well as in type 2 diabetes pancreata (n=20). Of note, 
the vast majority of autoantibody+ donors were seropositive for only a single autoantibody 
(constituting Pre-Stage 1 type 1 diabetes), with five seropositive for two autoantibodies 
(considered potentially Stage 1-2 type 1 diabetes (34), dysglycemia unknown). We identified five 
genes (BSCL2, DUT-N, EIF2AK3, ITCH and MNX1; Fold Difference (FD) range = 1.58-3.41) 
displaying increased expression in autoantibody+ pancreata compared to unaffected controls and 
a single gene, HNF4A, which was highly repressed in autoantibody+ pancreata (FD = 0.08 vs 
controls) but only marginally induced in the type 1 diabetes group (FD = 1.78). In contrast, five 
monogenic diabetes genes (DUT-N, EIF2AK3, GLIS3, ITCH and NR0B2) were significantly 
induced in type 2 diabetes pancreata compared to unaffected donor organs (Table 1). 
 The remaining 21 of the 45 monogenic diabetes genes w re either not expressed 
differentially or not amplified in control or T1D pancreata as shown in Table S5, whereas four 
genes (ABCC8, GCK, NKX2.2, and RFX6) demonstrated a trend towards repression but did not 
achieve statistical significance. In addition, we have previously shown that INS, IAPP and the 
INS-IGF2 read through mRNA levels are dramatically inhibited in type 1 diabetes pancreata (35). 
To address whether altered expression of these monogenic diabetes genes is indeed pancreas 
specific, we examined the expression of 19 genes alt red in type 1 diabetes pancreata by RTqPCR 
using total RNA isolated from 10 control and 10 type 1 diabetes human spleens, and found no 
genes differentially expressed in this organ (Table S6). 
 
Classification of monogenic diabetes genes into physiological groups reveals broad 
differential expression in type 1 diabetes pancreata. 
The monogenic diabetes genes were separated into four physiological classifications: 1) 
immune, 2) β-cell function, 3) β-cell development and 4) ER function/stress (Table S7), with 
knowledge that certain genes associate with multiple categories (Table S7).  
Of the seven monogenic diabetes genes examined from the immune physiological group 
(Table S7), normalized RTqPCR revealed significant differences in LRBA, SIRT1, STAT1, STAT3 
and STAT5B expression in type 1 diabetes versus unaffected pancre ta, with FDs ranging from 
2.75 to 3.89 (Table 1). For STAT5B a significant 3.59 FD was noted (Fig 1a). Widefield IF for 
STAT5B, insulin (INS), glucagon (GCG) and somatostatin (SST) with IF for islet (CD99) and 
exocrine cell markers (KRT19) and ISH for STAT5 (Fig. 1b), along with STAT5B confocal ISH-
IF (Fig. 1c) in unaffected and type 1 diabetes human p ncreata, reveals cytosolic expression of 
STAT5B most appreciably within the islets. These studies suggest that STAT5B co-localizes with 
glucagon and insulin in unaffected α- and β-cells, respectively (Fig. 1b and c). To demonstrate the 
uniformity of these results, we have included images of additional type 1 diabetes and control 
donor pancreata (Figs. S1 and S2). Most strikingly, we observed a number of islet cells that display 
only STAT5B expression with limited to no expression f either INS, GCG or SST in both 
unaffected and type 1 diabetes islets (Figs. 1c, S1 and S2).  
 We similarly observed significantly altered expression for numerous monogenic diabetes 
genes in the β-cell function group (Table 1), including DUT-N, DUT-M, GATA4, PLAGL1 and 
NR0B2, with the FDs ranging from 1.88-4.35 for type 1 diabetes compared to unaffected control 
pancreas. GATA4 expression FD 4.35 (Fig 2a) was also examined by IF and ISH-IF revealing 
primarily nuclear expression in both islets and the exocrine pancreas (Figs. 2b, S3 and S4).  
RTqPCR analysis of genes belonging to the β-cell development group (Table S7) identified 
altered expression in the type 1 diabetes pancreas for GATA6, GLIS3, HNF1B, MNX1 and 
TRMT10A (Table 1), with FDs ranging from 2.25-4.01 relative to control donor pancreata. 
Examination of GLIS3 FD 4.01 (Fig 3a) by IF and ISH-IF demonstrated expression in both islets 
and the exocrine pancreas in unaffected controls (Fig. 3b). Close examination, however, reveals 
an obvious decrease in islet specific expression of GLIS3 in the type 1 diabetes pancreas with no 
obvious change in the exocrine region (Figs. 3b, S5 and S6, yellow outlines). In addition, the 
combined ISH-IF (Fig. 3b, right) is consistent with decreased GLIS3 mRNA in the type 1 diabetes 
islet and demonstrates that exocrine expression is mo t likely specific to ductal epithelial cells 
based on GLIS3 mRNA colocalization (ISH) with IF for KRT19, a type 1 keratin specific to ductal 
cells (36). 
 The final set of monogenic diabetes genes examined are grouped based on their association 
with endoplasmic reticulum-ER function/stress (Table S7), with altered expression in type 1 
diabetes pancreata observed for BSCL2, CEL, ITCH and WFS1 (FD range from 2.2-4.41, Table 1).  
WFS1 (Wolframin, regulator of ER calcium homeostasis) expression FD of 4.41 (Fig 4a) was also 
evaluated by IF to evaluate WFS1 (37) protein localization in the human pancreas (Figs. 4b, S7 
and S8). Consistent with the IF data, ISH-IF identified WFS1 mRNA in the islet along with 
scattered expression in exocrine regions of the pancre s from type 1 diabetes and control donors 
(Fig. 4b, right). These data noted islet specific cytosolic expression with apparent colocalization 
involving both INS and GCG in unaffected control pancreas. Most strikingly, we consistently 
observed non-hormone expressing WFS1+ cells in the vast majority of islets from both control 
and type 1 diabetes pancreas. To confirm this observation, we utilized confocal microscopy using 
sections of unaffected control and type 1 diabetes pancreata co-stained for WFS1 (Fig. 4c) in 
conjunction with INS, GCG and SST. The combined z stacks for the overlay and each separate 
channel illustrate individual cells (insets and yellow arrows) that only express WFS1, having no 
co-registration with endocrine hormones. The overlay p nel (Fig. 4b) for the type 1 diabetes 
pancreas 6180 also revealed a potential islet exclusively expressing cells positive only for WFS1 
(green only islet, single INS positive cell in the lower middle). The existence of islets/cells 
exclusively positive for WFS1 is reproduced in other islets from control and type 1 diabetes patient 
pancreata (Figs. S7 and S8). To be clear, WFS1 only positive cells are also evident in islets that 
display hormone positivity as well (Figs. 4b, S7, and S8).  
Deeper analysis of the ER function and stress pathway reveals that the apex of the integrated 
stress response (ISR) is activated in type 1 diabetes pancreata 
EIF2AK3/PERK gene expression revealed a significantly i creased FD of 8.3 (Fig 5a). 
Using IF and ISH-IF in unaffected control and type 1 diabetes pancreata (Figs. 5b, S9 and S10), 
we noted EIF2AK3/PERK localization in both islets and the exocrine pancreas. The localization 
in control islets is consistently higher when compared with the exocrine tissue (Figs. 5b, S9), 
whereas EIF2AK3/PERK localization in the type 1 diabetes pancreas was more uniform in 
intensity in both the endocrine and exocrine tissue (Figs. 5b, S10). We then examined 30 ISR-
associated genes, identifying 20 that were significantly induced in type 1 diabetes versus control 
pancreas (Table 2), with FDs ranging from 2.4-18.11. The ISR contains three arms where ATF6 
(ARM1), IRE1⍺ (ERN1; ARM2) and each of the eIF2α kinases: PERK, HRI, PKR and GCN2 
(ARM3) constitute the apex of each arm.  RTqPCR data for genes at the apex of ARMs 1-3 of the 
ISR (Fig. 5c) demonstrate that all three ARMs are activ ted, including three of the four 
eIF2αkinases [EIF2AK3/PERK (Fig 5a), EIF2AK2/PKR and EIF2AK4/GCN2 (Fig 5c)]. These 
data therefore strongly implicate that the ISR is chronically activated in T1D pancreata, with 
disease duration for our T1D donor samples spanning 7 months to 57 years (Table S1) 
To evaluate a potential role for the ISR in pre-type 1 diabetes, we tested the expression 
levels of all 20 ISR genes showing altered expression in type 1 diabetes pancreata within our 
autoantibody+ cohort (Table 2).  We identified eight ISR-linked genes that showed significantly 
altered expression in pancreata from autoantibody+ onors with four of these being induced 
(DNAJB11, EIF2AK3, FEN1, and NELFA, Table 2). The remaining four dysregulated ISR genes 
showed a significant level of repression in autoantibody+ donor tissues associated with a 
remarkable inhibition at the apex of all three arms of the ISR (Table 2, Fig 5d). 
 
Discussion 
As a complement to traditional genetic linkage strategies, we utilized a transcriptomic analysis to 
test a novel hypothesis that genes classically associated with monogenic forms of diabetes (3-6) 
would be differentially expressed in human pancreas from individuals with type 1 diabetes or those 
at increased risk for the disease. Studies were conducted on tissues from donors that do not carry 
monogenic diabetes associated mutations, with features consistent with T1D or T2D [HLA, Age 
of onset, BMI, HbA1c and c-peptide (Table S1 and Fig S11)].  In support of this strategy, our data 
demonstrate that 24 of the 45 genes associated with monogenic diabetes displayed altered 
expression in pancreata from type 1 diabetes versus control donors, and six of these genes were 
also dysregulated in autoantibody+ organ donors, considered to have high risk (single 
autoantibody+) or pre-type 1 diabetes (≥2 autoantibody+). The uniformity of the repressed HNF4A 
expression across the entire autoantibody+ cohort further advances the notion that even a single 
autoantibody may have relevant prognostic value.  
The type 2 diabetes pancreas l o demonstrated altered expression of five monoge ic 
diabetes genes relative to unaffected control tissue. Not surprisingly, these genes fell primarily 
within the ER function/stress physiological group while expression of monogenic diabetes genes 
associated with all four physiological groups (i.e., immune, β-cell function, β-cell development, 
and ER function/stress) were altered in type 1 diabetes. Hence, genes exhibiting altered expression 
likely point toward mechanisms underlying type 1 diabetes and type 2 diabetes pathogenesis, 
respectively.  
Localization (IF) studies on select dysregulated monogenic diabetes and ISR genes from 
each physiological study group pinpointed genes that are expressed to a greater extent in the islets 
(e.g., STAT5B and WFS1) while others were expressed in both islet and exocrine regions of the 
pancreas (e.g., GATA4, GLIS3 and PERK). Hence, these data highlight a potential role for ISR 
activation within the exocrine pancreas in type 1 diabetes pathogenesis, in line with our previous 
studies demonstrating reduced pancreas mass (38; 39) and volume (40) as well as low serum levels 
of trypsinogen in recent-onset type 1 diabetes patients and pre-type 1 diabetes subjects (41). We 
also identified non-hormone expressing cells in human islets that were positive for either the 
transcription factor STAT5B or an ER calcium channel/regulator, WFS1. Although both of these 
proteins were sometimes co-registered with GCG, INSor ST, identifying α-, β- and δ-cells, 
respectively, in control and type 1 diabetes pancreata, there are cells scattered across the pancreas 
that express these proteins and are clearly hormone negative. We might speculate that these results 
represent a possible stem cell population, a state of d differentiation, cells exhausted of hormone 
at the time of death or a previously undetected islet cell type. We are currently attempting to 
identify unique surface markers that could facilitate cell sorting and single cell RNA-sequencing 
analysis to further characterize these cells 
We believe the power of our monogenetic strategy has been borne out in identifying a 
plethora of noteworthy genes coupled with their uniq e pancreatic localization, as well as the 
potential functional implications of their dysregulated expression. In addition to monogenic 
diabetes genes, we extended our studies to ISR-linked genes with 20 out of 30 ISR genes studied 
displaying altered expression in type 1 diabetes pancreata. These results included three of four 
eIF2α-dependent kinases (42), thus attendant with ISR (43) activation in type 1 diabetes 
pathogenesis trongly implicating an overarching, chronic stress re ponse (44; 45). Interestingly, 
we uncovered numerous additional loci with altered expression that are central to the regulation 
and function of each arm of the ISR pathway in type 1 diabetes pancreata, suggesting a global 
activation of the ISR in the type 1 diabetes pancreas, not simply extrapolated from the study of a 
single gene. The ISR can be induced by intrinsic stress associated, for example, with the 
accumulation of unfolded proteins in the ER mediate by PERK, or through extrinsic stressors 
including oxidative challenge (HRI), viral infection (PKR) or amino acid deprivation (GCN2) (42). 
While such stress responses may lead to activation of the UPR and/or ISR in type 2 diabetes (46-
50), a similar argument for the ISR in type 1 diabetes (47; 51-54) has been hypothesized, but not 
directly demonstrated. Indeed, prior reports have implicated ER stress and the UPR as potentially 
contributing toward inflammation and β-cell death in type 1 diabetes, but to our knowledge, this 
represents a first report demonstrating comprehensiv  activation of all three arms of the ISR in 
human type 1 diabetes pancreas tissue.  
Of note, our studies are restricted due to the inherent limitations of our organ donor study 
group such that more mechanistic studies are not easily implemented in archival tissue. To this 
end, future studies in human islets or live human pcreas organ slices could more directly address 
pathway-specific and physiologically relevant mechanisms. From a diagnostic standpoint, our data 
are all derived from organ donor pancreata which precludes any diagnostic assay in live patients, 
however we are beginning studies to address some of these markers in peripheral blood. We thus 
believe our data afford the diabetes community a rich opportunity to investigate potential 
therapeutics targeting numerous metabolic and pancre s intrinsic signaling pathways. Our 
observations in the type 1 diabetes pancreas taken in the context of a lifelong disease may be best 
described by the title of a review by Rutkowski and Kaufman entitled, “That which does not kill 
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FIGURE LEGENDS 
Figure 1. Monogenic diabetes genes were sorted into 4 physiological groups: Immune, β-cell 
Function, β-cell Development and ER Function/Stress (Table S7). a.) Scatter plot of gene 
expression data for STAT5B, a gene representing an Immune monogenic diabetes gene, studied 
using RTqPCR in human organ donor pancreata. Cq values from the Unaffected (control) and type 
1 diabetes cohorts were independently normalized using the geometric mean of three pancreas-
specific reference genes and the fold difference (FD) is calculated based on the ratio of the means 
(Methods). See Methods for statistical analysis [p-values and q-values (estimation of false 
discovery rates)]. N/D refers to N # of samples yielding no data, out of the total (D). b ) Wide Field 
immunofluorescence (IF) of STAT5B (green) and overlay with insulin (INS), glucagon (GCG) 
and somatostatin (SST) from a control and type 1 diabetes pancreas. Final panel in each row shows 
combined STAT5B in situ hybridization (ISH, RNAscope (green dots)) coupled with IF for CD99 
and KRT19. Magnification bars are 40µm. c.) Confocal imaging on a Nikon A1plus confocal 
microscope of STAT5B (green), insulin (INS), glucagon (GCG), and somatostatin (SST), 
showing an overlay of an islet from an unaffected an type 1 diabetes pancreas (left panels). 3D 
Z-stacks were constructed with a 2.5 µm step size and compressed to a 2D maximum intensity 
projection for display. Individual channels in black and white identify cells positive only for 
STAT5B and negative for the other endocrine hormones, illustrated with yellow arrows (overlay) 
and with insets in the respective black and white channels.  
 
Figure 2. a.) Scatter plot of RTqPCR data depicting expression levels for GATA4 a monogenic 
diabetes gene in the category β-cell Function (Table S7). The fold difference (FD) is calculated 
based on the ratio of the means (Methods). See Methods for statistical analysis [p-values and q-
values (estimation of false discovery rates)]. N/D refers to N # of samples yielding no data, out of 
the total (D).  b.) Wide Field immunofluorescence (IF) of GATA4 (green) and overlay with insulin 
(INS), glucagon (GCG) and somatostatin (SST) from a control and type 1 diabetes pancreas. Final
panel in each row shows combined GATA4 in situ hybridization (ISH, RNAscope (green dots)) 
coupled with IF for CD99 and KRT19. Magnification bars are 40µm. 
 
Figure 3. Scatter plot of RTqPCR data depicting expression levels for GLIS3 a monogenic diabetes 
gene in the category β-cell Development (Table S7). The fold difference (FD) is calculated based 
on the ratio of the means (Methods). See Methods for tatistical analysis [p-values and q-values 
(estimation of false discovery rates)]. N/D refers to N # of samples yielding no data, out of the 
total (D).  b.) Wide Field immunofluorescence (IF) of GLIS3 (green) and overlay with insulin 
(INS), glucagon (GCG) and somatostatin (SST) from a control and type 1 diabetes pancreas. 
Yellow outlines depict the islets to illustrate the significant reduction of GLIS3 in the T1D islet. 
Final panel in each row shows combined GLIS3 in situ hybridization (ISH, RNAscope (green 
dots)) coupled with IF for CD99 and KRT19. Magnification bars are 40µm. 
 
Figure 4. a.) Scatter plot of RTqPCR data depicting expression levels for WFS1 a monogenic 
diabetes gene in the category ER Function/Stress (Table S7). The fold difference (FD) is 
calculated based on the ratio of the means (Methods). See Methods for statistical analysis [p-values 
and q-values (estimation of false discovery rates)]. N/D refers to N # of samples yielding no data, 
out of the total (D).  b.) Wide Field immunofluorescence (IF) of WFS1 (green) and overlay with 
insulin (INS), glucagon (GCG) and somatostatin (SST) from a control and type 1 diabetes 
pancreas. Final panel in each row shows combined GATA4 in situ hybridization (ISH, RNAscope 
(green dots)) coupled with IF for CD99 and KRT19. Magnification bars are 40µm. c.) Confocal 
imaging on a Nikon A1plus confocal microscope of WFS1 (green), insulin (INS), glucagon 
(GCG), and somatostatin (SST), showing an overlay of an islet from an unaffected and type 1 
diabetes pancreas (left panels). 3D Z-stacks were constructed with a 2.5 µm step size 
and compressed to a 2D maximum intensity projection for display. Individual channels in black 
and white identify cells positive only for WFS1 and egative for the other endocrine hormones, 
illustrated with yellow arrows (overlay) and with insets in the respective black and white channels.  
 
Figure 5. a.) Scatter plot of RTqPCR data depicting expression levels for EIF2AK3/PERK a 
representative gene in Arm3 of the Integrated Stress Response (ISR) (see Graphical Abstract). The 
fold difference (FD) is calculated based on the ratio of the means (Methods). See Methods for 
statistical analysis [p-values and q-values (estimation of false discovery rates)]. N/D refers to N # 
of samples yielding no data, out of the total (D).  b.) Wide Field immunofluorescence (IF) of PERK 
(green) and overlay with insulin (INS), glucagon (GCG) and somatostatin (SST) from a control 
and type 1 diabetes pancreas. Final panel in each row shows combined PERK in situ hybridization 
(ISH, RNAscope (green dots)) coupled with IF for CD99 and KRT19. Magnification bars are 
40µm. c.) Scatter plots of RTqPCR data depicting expression levels for ISR genes from the apex 
of each ISR ARM 1-3 in type 1 diabetes versus unaffected control pancreata: ATF6, ERN1/IRE1⍺, 
EIF2AK2/PKR, EIF2AK3/PERK, EIF2AK4/GCN2. The fold difference (FD) is calculated based 
on the ratio of the means. See Methods for statistical analysis [p-values and q-values (estimation 
of false discovery rates)]. N/D refers to N # of samples yielding no data, out of the total (D). d.) 
Scatter plot of RTqPCR data depicting expression levels for genes significantly repressed in AAB+ 
(autoantibody positive) pancreata in each of the three Arms of the ISR: MBTPS1/S1P, 




Table 1. Tabulated fold differences (FD), p-values and q-values (estimation of false discovery 
rates) for the monogenic diabetes genes showing altered expression in type 1 diabetes (left), AAB+ 
(autoantibody positive) (middle) and type 2 diabetes (right) pancreata. Cq values from the 
Unaffected (control) and type 1 diabetes cohorts were independently normalized using the 
geometric mean of three pancreas-specific reference gen s and the FD calculated based on the 
ratio of the means (Methods). See Methods for statistical analysis (p-values and q-values). n refers 
to the number of independent pancreata in each cohort and the bold italics denote those genes 
showing altered expression (shaded rows) relative to control donors: Type 1 diabetes: 24 altered 
genes out of a total of 45 monogenic diabetes genes; AAB+: 6 altered genes; and type 2 diabetes: 
5 altered genes. * denotes genes where either the p-value (<0.05) and/or q values (≤ 0.024) 
approached significance. 
 
Table 2. Tabulated fold differences (FD), p-values and q-values for the ISR genes showing altered 
expression in type 1 diabetes (left), and autoantibody+ (right) pancreata. n refers to the number of 
independent pancreata in each cohort and the bold italics denote those genes showing altered 
expression.  20 out of 30 ISR genes tested showed differential expression in type 1 diabetes 
pancreata. Eight of the 20 genes altered in type 1 diabetes showed differential expression in the 














































































































































































































































































































































































































    
 
















































































































































































































































































































































































    Figure S11. Donor metadata for the Unaffected/Control, T1D  
    AAB+ and T2D. a) Body Mass Index (BMI kg/m2); b) Hemoglobin  
    A1c (HbA1c mmol/mol); c) C-peptide pmol/L and d) Disease  
    duration, years. 














































Monogenic Diabetes Genes 
 T1D (n=25-30) AAB+ (n=20-24) T2D (n=18-22) 
Gene FD p-Value q-Value FD p-Value q-Value FD p-Value q-Value 
APPL1 1.97 0.056* 0.029* 1.08 0.223 0.078 1.01 0.491 0.141 
BSCL2 2.14 0.021 0.012 1.70 0.013 0.009 1.31 0.234 0.080 
CEL 2.52 0.040 0.023 0.90 0.560 0.158 2.27 0.257 0.085 
DUT-M 2.87 0.001 0.001 1.16 0.657 0.174 5.91 0.178 0.067 
DUT-N 4.07 0.004 0.003 2.29 <0.001 0.001 3.11 <0.001 <0.001 
EIF2AK3 8.32 <0.001 <0.001 3.41 <0.001 <0.001 4.03 0.004 0.004 
GATA4 4.35 0.004 0.004 0.71 0.431 0.127 1.37 0.242 0.081 
GATA6 2.99 <0.001 0.001 0.91 0.243 0.081 1.84 0.208 0.076 
GLIS3 4.01 <0.001 0.001 1.05 0.435 0.127 3.13 0.052* 0.027* 
HNF1A 1.54 0.042 0.024 0.54 0.812 0.203 1.00 0.385 0.116 
HNF1B 3.44 <0.001 0.001 0.70 0.582 0.161 1.66 0.097 0.045 
HNF4A 1.78 0.072* 0.037* 0.08 0.006 0.005 1.53 0.953 0.231 
ITCH 2.81 0.003 0.003 2.54 <0.001 <0.001 3.41 <0.001 0.001 
KLF11 2.12 0.021 0.012 0.42 0.243 0.081 1.25 0.670 0.174 
LRBA 3.89 0.002 0.002 0.36 0.580 0.161 1.44 0.366 0.112 
MNX1 2.51 0.003 0.003 1.58 0.004 0.003 1.11 0.359 0.111 
NR0B2 1.88 0.037 0.022 1.04 0.497 0.141 2.41 0.002 0.002 
PLAGL1 2.87 0.001 0.001 1.14 0.624 0.168 1.56 0.155 0.062 
SIRT1 3.05 0.013 0.009 0.28 0.154 0.062 1.52 0.649 0.173 
STAT1 2.89 0.050* 0.027* 0.80 0.961 0.232 2.35 0.287 0.093 
STAT3 2.75 0.012 0.009 1.38 0.097 0.045* 1.46 0.160 0.063 
STAT5B 3.59 0.005 0.004 1.28 0.116 0.051 2.03 0.216 0.078 
TRMT10A 2.25 0.018 0.011 0.65 0.442 0.128 0.69 0.219 0.078 
WFS1 4.41 0.002 0.002 0.89 0.767 0.193 1.35 0.207 0.076 
 
Integrated Stress Response Genes 
 T1D (n=25-30) AAB+ (n=20-24) 
Gene FD p-Value q-Value FD p-Value q-Value 
ALS2 12.36 <0.001 <0.001 0.60 0.703 0.179 
ATF4 1.27 0.306 0.097 na   
ATF6 2.78 0.004 0.004 0.85 0.869 0.216 
BLOC1S1 1.48 0.379 0.115 na   
COL6A2 8.25 <0.001 <0.001 0.50 0.598 0.163 
DDIT3/CHOP 1.83 0.073 0.037 na   
DNAJB11 4.58 <0.001 <0.001 4.35 <0.001 <0.001 
DNAJB9 5.61 <0.001 <0.001 0.45 0.905 0.223 
DNAJC3 1.81 0.225 0.078 na   
EDEM1 18.11 <0.001 <0.001 1.20 0.113 0.050 
EIF2AK1 2.12 0.142 0.058 na   
EIF2AK2 2.90 0.015 0.010 0.20 0.043 0.024 
EIF2AK3 8.32 <0.001 <0.001 3.41 <0.001 <0.001 
EIF2AK4 4.47 0.002 0.002 0.79 0.170 0.065 
EIF2S1 2.14 0.082 0.039 na   
ERN1/IRE1a 5.86 0.012 0.009 0.28 0.002 0.002 
FEN1 8.37 <0.001 <0.001 2.47 0.001 0.001 
HSP90B1 4.07 0.002 0.002 0.56 0.358 0.111 
HSPA5 2.54 0.122 0.051 na   
MBTPS1 3.12 0.026 0.015 0.08 0.017 0.011 
MBTPS2 2.77 0.159 0.063 0.14 <0.001 0.001 
MSMO1 2.40 0.045 0.025 0.40 0.291 0.093 
MVK 6.43 <0.001 <0.001 0.97 0.204 0.076 
NELFA 7.48 <0.001 <0.001 1.65 0.017 0.011 
PDIA4 8.38 <0.001 <0.001 1.26 0.075 0.037 
PPP1R15A 9.48 <0.001 <0.001 0.47 0.689 0.176 
TMBIM6 4.42 <0.001 <0.001 0.76 0.689 0.176 
VCP 12.44 <0.001 <0.001 1.05 0.078 0.038 
XBP1s 3.81 0.138 0.057 na   
XBP1u 1.48 0.361 0.111 na   
Controls 
Unaffected 
           










































male African Am 
  




















6009 negative 45 
  
male Caucasian 3746.92 
 













19.7 cerebrovascular/stroke A* 02:01/02:01 B* 07:02/57:01 










female African Am 
  







6012 negative 68 
  
female Caucasian 983.07 
 







6013 negative 65 
  
male Caucasian 926.8 
 







6017 negative 59 
  
female Caucasian 3273.59 
 







6020 negative 60 
  
male Caucasian 933.42 
 







6024 negative 21 
  
male Caucasian 1165.12 
 







6030 negative 30.1 
  
male Caucasian 840.74 
 







6034 negative 32 
  
female Caucasian 1042.65 
 







6047 negative 7.8 
  







6048 negative 30 
  
male Caucasian 5928.21 
 







6055 negative 27 
  
male Caucasian 195.29 
 







6057 negative 22 
  
male Caucasian 5372.13 
 







6058 negative 27 
  
male Hispanic 3008.79 
 







6073 negative 19.2 
  
male Caucasian 228.39 
 
36 anoxia A*29/01, B*37/44, DR*13/16, 
DQ*05/06 
6075 negative 16 
  
male African Am 973.14 
 







6096 negative 16 
  
female African Am 983.07 
 







9098 negative 17.8 
  







6102 negative 45.1 
  







6103 negative 1.5 
  







6104 negative 41 
  
male Caucasian 6802.05 
 







6106 negative 2.9 
  
male Caucasian 2436.16 
 







6117 negative 0.33 
  
male Caucasian 1082.37 
 







6125 negative 0.42 
  
male Caucasian 3051.82 
 







6126 negative 25.2 
  
male Hispanic 291.28 
 







6129 negative 42.9 
  







6130 negative 5.2 
  
male Caucasian 1588.8 
 
18.5 head trauma A* 01:01, 03:01 DRB1* 03:01, 
15:01 DQA1* 01:02, 05:01 
DQB1* 02:01, 06:02 
6131 negative 24.2 
  
male Caucasian 334.31 
 







6134 negative 26.7 
  
male Caucasian 1188.29 
 







6137 negative 8.9 
  







6140 negative 38 
  







6144 negative 7.5 
  











6153 negative 15.2 
  







6160 negative 22.1 
  
male Caucasian 132.4 33/5.2 23.9 head trauma not listed 
6165 negative 45.8 
  
female Caucasian 1472.95 38/5.6 25 cerebrovascular/stroke A*01:01, 02:01 DRB1*13:01, 








44/6.2 25.2 cerebrovascular/stroke A*02:01, 24:02  DRB*01:03, 
04:04 DQA1*01:01, 03:01 
DQB1*03:02, 05:01 
6172 negative 19.2 
  
female Caucasian 2654.62 36/5.4 32.4 cerebrovascular/stroke A*03:01 , 68:02 DRB1*01:01 , 
13:03 DQA1*01:01 , 05:01 
DQB1*03:01 , 05:01 
6174 negative 20.9 
  
male Caucasian 993 
 
19.5 cerebrovascular/stroke A*02:05 , 26:01 DRB1*03:01 , 
07:01 DQA1*02:01 , 05:01 
DQB1*02:01 , 02:02 
6178 negative 24.5 
  
female Caucasian 1506.05 31/5.0 27.5 anoxia A*02:01 , 24:02 DRB1*04:01 , 
15:01 DQA1*01:02 , 03:01 
DQB1*03:01 , 06:02 
6179 negative 20 
  
female Caucasian 906.94 
 
20.7 head trauma A*02:01, 24:02 DRB*03:01, 
04:04 DQA1*03:01, 05:01 





male African Am 
  
15.4 birth defect A*02:01, 30:01 DRB1*01:02, 
03:02 DQA1*01:01, 04:01 
DQB1*04:02, 05:01 
6217 negative 0.58 
  
male Caucasian 433.61 
 
17.6 anoxia A*03:01, 03:01 DRB*04:07, 
08:01 DQA1*03:01, 04:01 
DQB1*03:01, 04:02 
6227 negative 17 
  
female Caucasian 910.25 
 
26.4 cerebrovascular/stroke A*02:01, 03:01 DRB1*04:01, 
13:02 DQA1*01:02, 03:01 
DQB1*03:02, 06:04 
6229 negative 31 
  
female Caucasian 2062.13 37/5.5 26.9 head trauma A*02:01, 24:02 DRB1*01:01, 
13:02 DQA1*01:02, 01:02 
DQB1*05:04, 06:04 
6232 negative 14 
  
female Caucasian 6454.5 
 
20.8 head trauma A*02:01, 24:02 DRB1*15:01, 
15:01 DQA1*01:02, 01:02 
DQB1*06:02, 06:02 
6233 negative 14 
  
male Caucasian 2403.06 37/5.5 21.9 anoxia A*01:01, 26:01 DRB1*01:01, 
13:01 DQA1*01:01, 01:03 
DQB1*05:01, 06:03 
6234 negative 20 
  
female Caucasian 2280.59 40/5.8 25.6 head trauma A*02:01, 11:01 DRB1*11:01, 
15:01 DQA1*01:02, 05:01 
DQB1*03:01, 06:02 
6235 negative 30 
  
male Caucasian 2681.1 
 
25.4 head trauma A*24:02, 68:01 DRB1*03:01, 
04:07 DQA1*03:01, 05:01 
DQB1*02:01, 03:02 
6271 negative 17 
  
male Caucasian 3796.57 
 




6278 negative 12 
  




6316 negative 6 
  
male Caucasian 1515.98 
 




6318 negative 10 
  
female Caucasian 1287.59 33/5.2 17.6 head trauma A*03:01, 03:01 
DRB1*04:04,11:01 
DQA1*03:01,05:01 
DQB1*03:01,03:02             
Type 1 
Diabetes 
           













Cause of Death HiRes HLA 
6025 mIAA+ 23.8 19 4.80 male Caucasian 
  







6026 mIAA+ 22.4 9 13.40 male Caucasian 
  







6031 mIAA+ 39 35 4.00 male Caucasian 
  


















6035 mIAA+ 32.1 28 4.10 male Caucasian 
  











28.7 12 16.70 female Caucasian 
  
23.4 head trauma A* 01:01/02:01 B* 08:01/27:05 






6040 mIAA+ 50 20 30.00 female Caucasian 
 







6041 negative 26.3 23 3.30 male Caucasian 
  









26.4 8 18.40 male Caucasian 
  









15 10 5.00 female African Am 
  







6051 mIAA+ 20.3 13 7.30 male Caucasian 
  







6054 mIAA+ 35.1 30 5.10 female Caucasian 
  










10.7 6 4.70 male African Am 
 







6063 mIAA+ 4.4 3 1.40 male Caucasian 
  











19.6 9 10.60 female Caucasian 
  







6067 negative 32.6 8 24.60 female Hispanic 
  









22.6 7 15.60 female Caucasian 
  









25.8 14 11.80 male Caucasian 
 







6081 negative 31.4 15 16.40 male Hispanic 79.44 
 







6113 mIAA+ 13.1 1.58 11.52 female Caucasian 
  











36.7 28 8.70 male Caucasian 
  











27.1 11 16.10 male Caucasian 
  
25.9 head trauma A*01:01 , 02:01 DRB1*01:01 , 
03:01 DQA1*01:01 , 05:01 
DQB1*02:01 , 05:01 
6196 GADA+ 
mIAA+ 
26.5 15 11.50 female African Am 158.88 
 
26.6 anoxia A*03:01 , 30:02 DRB1*12:01 , 
13:03 DQA1*01:01 , 05:01 
DQB1*02:01 , 05:01 
6205 mIAA+ 40.9 33 7.90 female Caucasian 46.34 
 
22.6 anoxia A*01:01 , 11:01 DRB1*04:01 , 
16:01 DQA1*01:02 , 03:01 




16.7 10 6.70 female African Am 
  
24.4 cerebrovascular/stroke A*23:01 , 24:02 DRB1*09:01 , 
13:02 DQA1*01:02 , 03:01 





24 4 20.00 female African Am 
 
91/10.5 24.4 anoxia A*02:01 , 03:01 DRB1*04:05 , 
12:01 DQA1*03:01 , 05:01 
DQB1*03:01 , 03:02 
6215 GADA+ 
mIAA+ 
34 15 19.00 male Caucasian 
 
64/8.0 26.6 anoxia A*02:01, 11:01 DRB1*01:03, 
04:01 DQA1*01:01, 03:01 
DQB1*03:02, 05:01 
6223 mIAA+ 61 52 9.00 male Caucasian 
  
23.4 cerebrovascular/stroke A*01:01, 29:02 DRB1*03:01, 
04:01 DQA1*03:01, 05:01 
DQB1*02:01, 03:02 
6224 negative 21 1.5 19.50 female Caucasian 
  
22.8 anoxia A*02:01, 11:01 DRB1*01:01, 




25 11 14.00 male Caucasian 
 
103/11.6 20.1 anoxia A*24:02, 24:02 DRB1*03:01, 




18 12 6.00 female Caucasian 
  
26 head trauma A*02:01, 29:01 DRB1*04:01, 
13:03 DQA1*03:01, 05:01 
DQB1*03:01, 03:02 
6241 mIAA+ 33 31 2.00 male Caucasian 
  
18.4 cerebrovascular/stroke A*02:01, 03:01 DRB1*03:01, 




39 19 20.00 male Caucasian 
  
19.5 head trauma A*02:01, 02:01 DRB1*01:01, 
04:01 DQA1*01:01, 03:01 
DQB1*03:02, 05:01 
6244 mIAA+ 34 28 6.00 male Caucasian 16.55 41/5.9 23.8 head trauma A*01:01, 02:06 DRB1*03:01, 
04:01 DQA1*03:01, 05:01 
DQB1*02:01, 03:02 
6247 mIAA+ 24 0.6 23.40 male Caucasian 155.57 
 
24.3 head trauma A*24:02 , 68:01 DRB1*04:04 , 
11:01 DQA1*03:01 , 05:01 
DQB1*03:01 , 03:02 
6258 mIAA+ 39 37 2.00 female Caucasian 
 
64/8.0 28.7 head trauma A*02:01 , 02:01 DRB1*04:01 , 
04:01 DQA1*03:01 , 03:01 
DQB1*03:02 , 03:02 
6261 GADA+ 
mIAA+ 
16 14.16 1.84 male Caucasian 
 
55/7.2 20.7 anoxia A*03:01 , 30:01 DRB1*01:01 , 
04:01 DQA1*01:01 , 03:01 




44 8 36.00 male African Am 
  




6264 negative 12 9 3.00 female Caucasian 
 
74/8.9 22 DKA A*23:01 , 32:01 DRB1*03:01 , 
04:04 DQA1*03:01 , 05:01 
DQB1*02:01 , 03:02 
6265 GADA+ 
mIAA+ 
11 8 3.00 male Caucasian 19.86 
 
12.9 cerebrovascular/stroke A*03:01 , 32:01 DRB1*03:01 , 
04:01 DQA1*03:01 , 05:01 





30 23 7.00 male Caucasian 
 




6298 mIAA+ 29 26 3.00 male African Am 
 
122/13.3 24.3 anoxia A*24:02, 74:01 
DRB*04:05,13:03 
DQA1*02:01,03:01 
DQB1*02:02,02:02   
6299 mIAA+ 32 23 9.00 male Caucasian 
  










45 10 35.00 female Caucasian 
  






52 25 27.00 male Caucasian 
 







27 16 11.00 female Caucasian 
 




6322 mIAA+ 22 17 5.00 male Caucasian 
  






29 2 27.00 male Hispanic 
 







20 6 14.00 female African Am 46.34 
 




6327 mIAA+ 71.2 57 14.20 male Hispanic 
  





39 20 19.00 male Hispanic 
 






22 18 4.00 male Caucasian 
  




6337 mIAA+ 20.6 5 15.60 female Caucasian 
 




6341 mIAA+ 26 15 11.00 male Caucasian 
 




6360 mIAA+ 4.8 2.5 2.30 female Caucasian 
 




6362 GADA+ 24.9 0 
 












6380 negative 11.6 0 
 




















29.1 0.6 28.50 female Hispanic 609.04 53/7.0 42.5 cerebrovascular/stroke A*30:02,31:01 B*18:01,40:02 
DRB1*03:01,04:07 
DQA1*05:01,03:01 
DQB1*02:01,03:02             
Aab+ 
           













Cause of Death HiRes HLA 
6044 GADA+ 41.4 
  
male hispanic 4485.05 
 







6090 GADA+ 2.2 
  
male Hispanic 1767.54 
 







6101 GADA+ 64.8 
  
male Caucasian 8665.58 
 







6123 GADA+ 23.2 
  







6151 GADA+ 30 
  
male Caucasian 1817.19 
 
24.2 anoxia A*02:01 , 24:02 DRB1*01:01 , 
07:01 DQA1*01:01 , 02:01 
DQB1*02:02 , 05:01 
6154 GADA+ 48.5 
  
female Caucasian BD 
 







6170 GADA+ 34.5 
  
female African Am 1419.99 52/6.9 36.9 anoxia A*29:02 , 74:01 DRB1*04:01 , 
13:03 DQA1*02:01 , 03:01 
DQB1*02:02 , 03:01 
6181 GADA+ 31.9 
  
male Caucasian 198.6 
 
21.9 head trauma A*03:01 , 11:01 DRB1*01:01 , 
04:01 DQA1*01:01 , 03:01 
DQB1*03:02 , 05:01 
6184 GADA+ 47.6 
  
female Hispanic 1132.02 
 
27 head trauma A*02:06 , 68:03 DRB1*04:07 , 
04:07 DQA1*03:01 , 03:01 





male African Am 5785.88 37/5.5 28.2 head trauma A*02:02 , 24:02 DRB1*03:02 , 
07:01 DQA1*02:01 , 04:01 









6301 GADA+ 26 
  




6303 GADA+ 22 
  




6310 GADA+ 28 
  
female Hispanic 3488.74 
 




6314 GADA+ 21 
  
male Caucasian 493.19 
 




6347 mIAA+ 8.5 
  
male Caucasian 1079.06 
 












6397 GADA+ 21.16 
  




6400 GADA+ 25.15 
  




6421 GADA+ 6.73 
  




















6433 GADA+ 24 
  
male Hispanic 1469.64 34/5.3 30.8 head trauma A*30:02,68:01 B*08:01,45:01 
DRB1*04:05,12:01 
DQA1*03:01,05:05 
DQB1*03:02,03:01   
6437 GADA+ 27.4 
  
male Caucasian 2062.13 39/5.7 24.2 head trauma A*01:01,23:01 B*08:01,18:01 
DRB1*03:01,11:04 
DQA1*05:01,05:01 
DQB1*02:01,03:01             
Type 2 
Diabetes 
           













Cause of Death HiRes HLA 
6028 negative 33.2 17 16 male African Am 7414.4 
 














6124 negative 62.3 3 59 male Caucasian 943.35 
 














6133 negative 45.8 20 25 female Caucasian 278.04 
 
40.2 anoxia no info 
6139 negative 37.2 1.5 35 female Hispanic 198.6 
 







6142 mIAA+ 29.8 14 16 female Hispanic 62.89 
 







6149 GADA+ 39.3 16 23 female African Am 3823.05 
 







6188 negative 36.1 0 36 male Hispanic 1141.95 55/7.2 30.6 anoxia A*02:02 , 66:01 DRB1*12:01 , 
14:01 DQA1*01:02 , 05:01 
DQB1*03:01 , 06:04 
6249 mIAA+ 45 15 30 female Asian 1380.27 
 
32.3 stroke A*02:01 , 24:02 DRB1*04:05 , 
04:05 DQA1*03:01 , 03:01 
DQB1*04:02 , 04:02 
6252 negative 20 
  
male Caucasian 46.34 115/12.7 37.8 head trauma A*02:06 , 24:02 DRB1*08:02 , 
14:02 DQA1*04:01 , 05:01 
DQB1*03:01 , 04:02 
6255 negative 55 6 49 male Caucasian 920.18 
 
29.4 stroke A*02:01 , 11:01 DRB1*11:01 , 
12:01 DQA1*05:01 , 05:01 
DQB1*03:01 , 03:01 
6272 negative 57 10 47 female African Am 2499.05 
 




6273 negative 45 2 43 female African Am 1049.27 
 




6277 negative 48 10 38 male African Am 155.57 
 




6280 mIAA+ 47 10 37 male African Am 1228.01 
 








6297 mIAA+ 60 3 47 male Caucasian 1069.13 
 




6300 GADA+ 67 >10 
 




6304 negative 52 25 27 female Hispanic 774.54 
 




6308 negative 13 1 12 female Caucasian 1721.2 
 









Table S1. Subject Metadata. 
ITEM TO CHECK IMPORTANCE CHECKLIST METHOD DETAILS
EXPERIMENTAL DESIGN
Definition of experimental and control  groups E ✔
Number within each group E ✔ >20
Assay carried out by core lab or investigator's lab? D ✔ Investigator's lab
Acknowledgement of authors' contributions D ✔
SAMPLE
Description E ✔
     Volume/mass of sample processed D
    Microdissection or macrodissection E Macro
Processing procedure E ✔
     If frozen - how and how quickly? E snap
     If fixed - with what, how quickly? E N/A
Sample storage conditions and duration (especially for FFPE samples) E ✔ Frozen in RNAlater
NUCLEIC ACID EXTRACTION
Procedure and/or instrumentation E ✔
     Name of kit and details of any modifications E ✔ Qiagen RNeasy Plus Mini Kit #74134
     Source of additional reagents used D ✔ Worthington DNase I LS006344
Details of DNase or RNAse treatment E ✔
Contamination assessment (DNA or RNA) E ✔
primer sets that span exon/intron boundaries in 
RNA only qPCR reaction
Nucleic acid quantification E ✔
     Instrument and method E ✔ Nanodrop 2000C
     Purity (A260/A280) D ✔
     Yield D ✔
RNA integrity method/instrument E
    RIN/RQI or Cq of 3' and 5' transcripts E
    Electrophoresis traces D
 Inhibition testing (Cq dilutions, spike or other) E ✔
REVERSE TRANSCRIPTION
Complete reaction conditions E ✔ 65° 5 m, 42° 2 m, 42° 50 m, 70° 15 m, 37° 20 m
     Amount of RNA and reaction volume E ✔ 1 ug RNA 20 ul reaction
    Priming oligonucleotide (if using GSP) and concentration E ✔ oligo d(T) 0.5 ug/ul stock 
     Reverse transcriptase and concentration E ✔ Invitrogen SuperScript II # 100004925
     Temperature and time E ✔
Manufacturer of reagents and catalogue numbers
D ✔
NEB Rnase H # M0297L, Invitrogen RnaseOUT # 
100000840, Invitrogen First Strand 5x buffer # 
Y02321
Cqs with and without RT D ✔
Storage conditions of cDNA D ✔ negative 20 C
qPCR TARGET INFORMATION
If multiplex, efficiency and LOD of each assay. E N/A
Sequence accession number E ✔ Table S2
Location of amplicon D ✔ Table S3
     Amplicon length E ✔ Table S3
     In silico specificity screen (BLAST, etc) E ✔ PrimerBlast
     Pseudogenes, retropseudogenes or other homologs? D
          Sequence alignment D ✔ PrimerBlast
     Secondary structure analysis of amplicon D ✔ PrimerBlast
Location of each primer by exon or intron (if applicable) E ✔
     What splice variants are targeted? E ✔ when possible all 
qPCR OLIGONUCLEOTIDES
Primer sequences E ✔ Table S3
RTPrimerDB Identification Number D N/A
Probe sequences D N/A
Location and identity of any modifications E No mod
Manufacturer of oligonucleotides D ✔ Invitrogen
Purification method D ✔ manufacturer's protocol
qPCR PROTOCOL
Complete reaction conditions E ✔
     Reaction volume and amount of cDNA/DNA E ✔ 25 ul 10 ng
     Primer, (probe), Mg++ and dNTP concentrations E ✔ 600 nM
     Polymerase identity and concentration E ✔
Thermo Luminaris Color HiGreen Fluorescein 
qPCR Master Mix
     Buffer/kit identity and manufacturer E ✔
     Exact chemical constitution of the buffer D Manufacturer
     Additives (SYBR Green I, DMSO, etc.) E SYBR
Manufacturer of plates/tubes and catalog number D ✔ BioRad iCycler iQ PCR plates 2239441
Complete thermocycling parameters E ✔ 50° 2 m, 95° 10 m, 95° 15 s, 60° 1 m 40 cycles
Reaction setup (manual/robotic) D Manual
Manufacturer of qPCR instrument E Biorad MyiQ
qPCR VALIDATION
Evidence of optimisation (from gradients) D ✔
Specificity (gel, sequence,  melt, or digest) E Melt
For SYBR Green I, Cq of the NTC E ✔
Standard curves with slope and y-intercept E N/A
     PCR efficiency calculated from slope E N/A
     Confidence interval for PCR efficiency or standard error D N/A
     r2 of standard curve E N/A
Linear dynamic range E ✔
     Cq variation at lower limit E ✔
     Confidence intervals throughout range D ✔
Evidence for limit of detection E ✔
If multiplex, efficiency and LOD of each assay. E N/A
DATA ANALYSIS
qPCR analysis program (source, version) E ✔ RefFinder, Prism 6
     Cq method determination E ✔ BioRad iCycler iQ 
     Outlier identification and disposition E No
Results of NTCs E ✔
Justification of number and choice of reference genes E ✔
RefFinder, Δ Cq, NormFinder, BestKeeper, 
geNorm
Description of normalisation method E ✔ geNorm
Number and concordance of biological replicates D
Number and stage (RT or qPCR) of technical replicates E ✔ 2 replicates
Repeatability (intra-assay variation) E ✔
Reproducibility (inter-assay variation, %CV) D ✔
Power analysis D
Statistical methods for result significance E ✔ one way ANOVA, student's t-test, linear regression
Software (source, version) E ✔ Graphpad Prism 8
Cq or raw data submission using RDML D Raw only





































 3p14.3  
3:57,227,736-
57,273,470 
 -Adaptor Protein, 
Phosphotyrosine 
Interaction, PH domain, 
and leucine zipper 
containing 1 
-Dominant 








-B lymphocyte kinase 
-Dominant 
















































Am. J. Hum. Genet. 95: 








initiation factor 2-alpha 
kinase 3 (PERK) 
-Recessive 
 
 X  X  Wolcott-Rallison 
syndrome  










































-GATA-binding factor 6 
-Dominant 






Nat Genet.  44(1):20-2, 
2011. 






























-Hepatocyte nuclear factor 
1-alpha 
-Dominant 
3      Nature.  384(6608):455
-8, 1996. 









-Hepatocyte nuclear factor 
1-beta 
-Dominant 
5 X    Renal cysts and 
diabetes syndrome 
pancreatic agenesis 







-Hepatocyte nuclear factor 
4-alpha 
-Dominant 







-Immediate early response 
3-interacting protein 1 
-Recessive 



















J Allergy Clin Immunol 







-Spontaneous or dominant 
 







-E3 Ubiquitin Protein 
Ligase 
-Recessive 





Am J Hum Genet. 








sensitive K+ channel 
-Spontaneous or dominant 
 
13 X X X  Hyperinsulinemic 
Hypoglycemia 







-Krueppel-like factor 11 
-Dominant 









responsive and beige-like 
anchor protein 
-Recessive 












-motor neuron and 
pancreas homeobox 1 
-Recessive 
 X  X  Neonatal Diabetes; 
Currarino 
Syndrome 
Diabetes Metab.   
39(3):276-80, 2013. 













































Subfamily 0 Group B 
Member 2 (SHP) 
 X    Diabetes associated 













-Paired box gene 4 
-Dominant 








-Paired box protein Pax-6 
-Recessive 
 











cofactor of hepatocyte 
nuclear factor 1 α 
-Recessive 
 X  X  Early-onset non-
autoimmune 
diabetes with 















4 X  X  Permanent neonatal 
diabetes +/- 
pancreatic agenesis 












 X X   transient neonatal 
diabetes mellitus. 
Hum. Molec. Genet. 9: 
453-460, 2000. 
Hum. Genet. 110: 139-







factor 1 subunit alpha 
-Recessive 
 
 X  X  cerebellar  and 
pancreatic agenesis 
Nat 







-Regulatory factor X, 6 
-Recessive 
 



















    X Late onset 7,12, 15 
and 27 yo T1D 
diagnosis 
Cell Metabolism 17: 




 1q24.2  
1:169,463,908-
169,485,969 
-solute carrier family 19 
member 2 (Thiamine 
transporter 1) 
-Recessive 






Pediatric Diabetes  
13(4):314-21, 2012. 







-solute carrier family 2 
member 2 (GLUT2) 
-Recessive 









-Signal transducer and 
activator of transcription 1 
-Dominant 
    X Immunodeficiency 
31A,C; Gain-of-
function mutations 
in STAT1 can cause 
an IPEX-like 
phenotype 








-Signal transducer and 
activator of transcription 3 
-Dominant 















-Signal transducer and 
activator of transcription 5 












The annotation of this table was derived from data associated with the University of Exeter Molecular 
Genetics Laboratory (http://www.diabetesgenes.org/sites/default/files/tngs_genes_v4.pdf) and the 
Online Mendelian Inheritance in Man® (OMIM®) site (https://www.omim.org/). Genomic coordinates 
are derived from the reference genome GRCh38. 
* The GLIS3 gene associates with the markers: rs10758593; rs7020673; and rs6476839 (Immunobase 
https://www.immunobase.org/disease/T1D/). 
** The IL2RA gene associates with the markers: 
rs61839660; rs12251307; rs2104286; rs41295121; rs7090530; and rs10795791. 
*** The INS gene associates with the markers: 






























     Wolfram syndrome 
(Diabetes insipidus, 
diabetes mellitus, 











-Zinc finger protein 57 
homolog 
-Recessive 




GENE FORWARD REVERSE ACCESSION # 
ABCC8 ATGCTGCTCTTCGTCCTGGT CAAACTTGATGGTCTTGGTGATG NM_001287174.1 
ALS2 TCTGACTGAAGATGGTGAGGTC ATTCTCTCCCCACATGTACGC NM_020919.3 
APPL1 TTTGTTCTTCGGACATCAAGCG GTTTTGCCAGTCCAACAGAATCA NM_012096.2 
ASNS TGAGATAGAAACTGTGAAGAACAACCT TAGCAGCCAGTAAATCGGGG NM_133436.3 
ATF4 TCTAAAAGAGAGGGCGGATTCC CTACAGCACTCTATGTACAAGCACA NM_182810.2 




BLOC1S1 CCTCAATGTGGGTGTGGCC CGAGCCCAGTTCTCCACATC NM_001487.3 
BSCL2 TATATGCCGACAGTCAGCCAC CCATACATCAGCACCCGATCA NM_001122955.3 
CEL GACGCCAATCTGCCAGGTAA CGGATGAGGCCCTTGTTGTAG NM_001807.4 
COL6A2 AGCCTACGGAGAGTGCTACAA CTCCAAATTCACCCTTCTCTCCTTT NM_001849.3 
DDIT3/CHOP CCTGGAAATGAAGAGGAAGAATCAA TCTGACTGGAATCTGGAGAGTGA NM_001195057.1 
DNAJB9 TCGGAGGGTGCAGGATATTAGA TTGATTTGGCGCTCTGATGC NM_012328.2 
DNAJB11 GGCTCCCCAACTTTGACAAC AGCTGTTTGATACCTTCTCTCGC NM_016306.5 
DNAJC3 TCAGTGAAGTTCGGGAATGTCTT TAGCATCTGTGTATCTGCCATCT NM_006260.4 
DUT-M TTACGTCTCTGCTTCGCTCAG CGCCTTAGGAAGCTCGCC NM_001025248.1 
DUT-N GTCTCCTCGCTCGCCTTC CGCTTACTGGGTGAAATGGC NM_001948.3 
EDEM1 ATATGGTGCCCTCCCTGAGA GGATTCTTGGTTGCCTGGTAGA NM_014674.2 
EIF2AK1 CGAGTCTGCCTGTCCTTATGTT TCGGTGCACAATTCCCATGT NM_014413.3 
EIF2AK2 AATTGGCCGCTAAACTTGCA GATGATTCAGAAGCGAGTGTGC NM_001135652.2 
EIF2AK3 CACACAGGACAAGTAGGGACC GTTAAGGTCCTGACTCTCTCCATC NM_004836.6 
EIF2AK4 CTCGGCATCAAGTTACAGGTCTT CCTTCGTTTGATGAAAGCCACAA NM_001013703.3 
EIF2B1 GACTCACGCCTACTCCAGAG GGCCATTTTCTTACCTGACAAATCA NM_001414.3 
EIF2S1 AGAGACCTGGATATGGTGCCTA AGCCACTTCAATATCTGCTCGA NM_004094.4 
ERN1/IRE1α TCCAGTTCTTCCAGGACGTGA TGATGTTCTCCCGCCAGTC NM_001433.4 
FEN1 CTACCGAGGACATGGACTGC CCACAAACTGTTCCTGGTTCAG NM_004111.5 
FOXO3 TAGGGTCCTGAGAACTTCTGAGTTC CCAGGGTCTGTAAAACTGCAAA NM_001455.3 
FOXP3 TTCATCTGTGGCATCATCCGAC GAGCGTGGCGTAGGTGAAA NM_001114377.1 
GATA4 CTCTACATGAAGCTCCACGGG TGAAGGAGCTGCTGGTGTCTTA NM_001308093.1 
GATA6 AGCAAGATGAACGGCCTCA TGGTAGTTGTGGTGTGACAGT NM_005257.5 
GCK AACAATGTCGTGGGGCTTCT TGATGGTCTTCGTAGTAGCAGGA NM_000162.3 
GLIS3 TGGACACCAAACCTTATGCTTGT CTGGACCGCAACTTTTTCCTT NM_001042413.1 
HNF1A CTCATCACCGACACCACCAA GCTGGAGGACACTGTGGG NM_000545.6 
HNF1B TGTCAGGAGTGCGCTACAG GGGAGAGGCTGTGGATATTCG NM_001304286.1 
HNF4A CTCGTTGAGTGGGCCAAGTA GTAGTCATTGCCTAGGAGCAGC NM_001287182.1 
HSP90B1 GTGAAAAGCGGCCCGAC CAAGTCCCCTTCGATCGCAG NM_003299.2 
HSPA5 TTTTAATGATGCCCAACGCCA CAGCTGCCGTAGGCTCG NM_005347.4 
IER3IP1 GAGAGAAATCGCTTGGACTTCG TGGCACTCTCATCACGGTTC NM_016097.4 
IL2RA GGGGACTGCTCACGTTCAT GGATCTCTGGCGGGTCATC NM_001308243.1 
ITCH ATCATGTGGTTTTGGCAGTTTGTTA AGAATTTCTGTGGTCCATTGCTCC NM_001324197.1 
KCNJ11 CAGCATCCACTCCTTCTCGTC GGGCACTCCTCAGTCACCAT NM_001166290.1 
KLF11 CCCATCTTCGCACTCACACA TGACAGCTCATCCGAACGAG NM_001177718.1 
LRBA TGCTCATCAAGGTGCTGTACAAG TTATCCCAGAAGCCACAGACG NM_006726.4 
MAFB AAGAGAGCAACGAGGAAAGGAG GAGCAGGCAATAAAACTGATGAGA NM_005461.4 
MBTPS1 TGGACGCCTTCAACTATGCC GCTGTTAATTCCCACACCTTGTC NM_003791.3 
MBTPS2 TCCCAGTTAGAGCATACAAACGA TTGCTTCAACTGCTTTCCGG NM_015884.3 
MNX1 GGAGCACCAGTTCAAGCTCA AATCTTCACCTGGGTCTCGG NM_005515.3 
MSMO1 GCTTTGGTTGTGCAGTCATTGA GGTCACCCATGCCCAAAGAA NM_001017369.2 







NEUROG3* CCGGTAGAAAGGATGACGCC TGCCAACTCGCTCTTAGGC NM_020999.3 
NELFA AGAACCTGTCCCTCACGAGA GGCACGGGTTCTCTCGG NM_005663.4 
NFE2L2 CTCCACAGAAGACCCCAACC AAGTAGCAGGTGAGGGCATG NM_006164.5 
NKX2.2 TACTCCCTGCACGGTCTGG CCGCTTTCGCTTCTTGCC NM_002509.3 
NR0B2 TTCAACCCCGATGTGCCAG GATAGGGCGAAAGAAGAGGTCC NM_021969.2 
PAX4 CACGGCTCAGGTCACCAG CCAGACCCTCACCGTGTC NM_006193.2 
PAX6 GTTGGTATCCGGGGACTTCG TCTCTCAAACTCTTTCTCCAGGG NM_001310159.1 
PCBD1 TTCAAAGACTTCAACAGGGCCT GGTGGTCCAGTTTCTCAGCC NM_000281.3 
PDIA4 CCTTATGACTACAACGGCCCA TCAGGTTGTTAGCGGCATCC NM_004911.4 
PDX1 GATGAAGTCTACCAAAGCTCACG ACATGACAGCCAGCTCCAC NM_000209.3 
PLAGL1 CCCACGACCCCAACAAAATG CCAGGTGCCTCTTATAGCCC NM_001317157.1 
PPIA GTGGTATAAAAGGGGCGGGAG TGCTGTCTTTGGGACCTTGT NM_001300981.1 
PPP1R15A GCTCTTATCGGTTCCCATCCC ATGTGTCTGGGCGGCTG NM_014330.3 
PSEN1 CCAGAGGAAAGGGGAGTAAAACT GGTTGTGTTCCAGTCTCCACT NM_000021.3 
PTF1A CGACCCTGATTATGGCCTCC GATCTTCAGCCGAGTCTGGG NM_178161.2 
RFX6 ATTTCAGGCAGCACAGACACT TGACCTTCCATTTTGTTTGCTGG NM_173560.3 
SIRT1 ACTTCGCAACTATACCCAGAACA TGTTGCAAAGGAACCATGACAC NM_001314049.1 
SLC2A2 AGGGGAGCACTTGGCACTT GGTATCTGGGGCTTTCTGGAC NM_000340.1 
SLC19A2 AGCCAGACCGTCTCCTTGTA ACAGCAACAGCACCCAGTAA NM_001319667.1 
STAT1 GTGATCTCCAACGTCAGCCA TGGCGTTAGGACCAAGAAGC NM_139266.2 
STAT3 GGAAAGTATTGTCGGCCAGAGA TTCAGCACCTTCACCATTATTTCCA NM_213662.1 
STAT5B TGCTTGGAAGTTTGATTCTCAGG CTTCACGTATCCATCAACAGCTT NM_012448.3 
TMBIM6 TGGTCACTCATTTCATTCAGGCT ATCAGCCAAATCATCAATATCAGGG NM_003217.2 
TP53 ATTTCACCCTTCAGATCCGTGG TTATGGCGGGAGGTAGACTGA NM_001126115.1 
TRMT10A AGCACCCTTCGCCTTATTATTGA TGTCAAGTAAAACTGCACAGGATG NM_152292.4 
VCP AGGGGAGCCTATCAAACGAGA TCTAGGAGGCTTCACACCAATTG NM_001354927.1 
WFS1 TGCGTCTGAAGGTGGTCAAG GTGGGGATGATGGTGGACAG NM_006005.3 
XBP1s GTGAGTCCGCAGCAGGTG GGGTCCTTCTGGGTAGACCT NM_001079539.1 
XBP1u** CGCACCTGAGCCCCGA CTAAATCTACCACTTGCTGTTCC NM_005080.3 
ZFP57 GTGAAGAAGAAGCCAGTCACCTT GATGGACAAACTCTCTCCACTGT NM_001109809.2 
 
Table S4. Primer sequences 
 
*PRIMER SET(S) DID NOT AMPLIFY  
































Table S5. Monogenic diabetes genes which did not display altered gene expression. 
ND = no amplification; *Insulin (INS) data published previously: Cell Metab. 2017 Sep 5;26(3):568-




Monogenic Diabetes Genes 




ABCC8 0.45 0.667 0.174 
BLK ND   
DNAJC3 1.85 0.221 0.078 
FOXP3 ND   
GCK 0.51 0.625 0.168 
IER3IP1 1.53 0.266 0.087 
IL2RA ND   
INS*     
KCNJ11 1.49 0.409 0.122 
NEUROD1 ND   
NEUROG3 ND   
NKX2.2 0.41 0.121 0.051 
PAX4 ND   
PAX6 1.30 0.594 0.163 
PCBD1 1.51 0.166 0.064 
PDX1 1.45 0.099 0.045 
PTF1A 1.55 0.103 0.046 
RFX6 0.87 0.923 0.226 
SLC19A2 2.13 0.118 0.051 
SLC2A2 2.38 0.098 0.045 

























Table S6. Normalized RTqPCR data comparing control to T1D spleen. GATA4 and 
MNX1 did not amplify. RefFinder 
(http://150.216.56.64/referencegene.php?type=reference) was utilized to determine 
spleen reference genes, CALM1 and MAFB. Normalization factors were calculated 
using the geometric mean of relative quantities for both control and T1D samples. 








 HUMAN SPLEEN GENE EXPRESSION 
GENE FOLD DIFFERENCE p Value CONTROL T1D 
EIF2AK3 1.27 1.0 0/10 0/10 
STAT5B 1.06 0.836 0/10 0/10 
WFS1 1.35 0.780 0/10 0/10 
GATA4 ND    
GLIS3 0.96 0.618 0/10 0/10 
LRBA 1.42 1.0 0/10 0/10 
STAT1 1.13 1.0 0/10 0/10 
HNF1B 0.71 0.714 1/10 1/10 
SIRT1 1.52 0.893 0/10 0/10 
GATA6 1.99 0.308 0/8 0/10 
ITCH 1.14 0.893 0/10 0/10 
STAT3 0.95 0.671 0/10 0/10 
MNX1 ND    
PLAGL1 1.05 0.836 0/10 0/10 
CEL 0.889 0.826 0/10 0/9 
TRMT10A 1.36 0.950 0/10 0/10 
BSCL2 0.95 0.950 0/10 0/10 
APPL1 1.05 0.836 0/10 0/10 
KLF11 1.94 0.702 0/9 0/10 
Physiological Grouping of Monogenic Diabetes Genes 
Immune β -cell Function β-cell Development ER Function/Stress 
FOXP3      XR ABCC8  AR/AD GATA4                AD BSCL2             AR 
IL2RA APPL1         AD GATA6                AD CEL                 AD 
LRBA       AR BLK             AD GLIS3                  AR DNAJC3          AR 
SIRT1       AR CEL             AD HNF1B                AD DUT-N             AR  
STAT1      AD DUT-N         AR  MNX1                  AR  DUT-M            AR 
STAT3      AD DUT-M        AR NEUROD1          AR EIF2AK3         AR  
STAT5B   AR GCK            AR NEUROG3          AR GATA4            AD 
 GATA4        AD NKX2-2               AR GATA6            AD 
 HNF1A        AD PAX4                  AD GLIS3              AR 
 HNF1B        AD PAX6                  AR HNF4A            AD 
 HNF4A        AD PDX1                  AR IER3IP1           AR 
 INS              AD PTF1A                AR ITCH                AR 
 KCNJ11      AD  RFX6                  AR SIRT1              AD 
 KLF11         AD SIRT1                 AR STAT1             AD 
 NR0B2        AD TRMT10A           AR STAT3             AD 
 PCBD1        AR  WFS1              AR 
 PLAGL1     IMP   
 SLC19A2    AR   
 SLC2A2      AR   
 TRMT10A   AR   
 ZFP57         IMP   
Table S7. Monogenic diabetes genes sorted into 4 physiological groups: Immune, b-cell 
Function, b-cell Development and ER Function/Stress. Bold and Italics indicates inclusion in another 
Group. The following denotes the genetic inheritance pattern for each monogenic diabetes gene:
Autosomal Recessive (AR); Autosomal Dominant (AD); Imprinted (IMP); X-Linked Recessive (XR). 
 
